← Eichor
Study identifier: NCT06820255 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Condition: Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable · Upper Tract Urothelial Cancer  ·  Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

PhasePhase 4
Planned participants135
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to prospectively observe whether certain alterations in some genes related to the DNA repair mechanism are related to better response to platinum-based chemotherapy used to treat metastatic bladder or urothelial cancers.

This description comes directly from the study's public registry record.

Talk to the study team

Roberto Iacovelli, Prof  ·  +390630157373  ·  roberto.iacovelli@policlinicogemelli.it

Always discuss trial participation with your own doctor first.

Locations (1)

Fondazione Policlinico Universitario A. Gemelli IRCCSRome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06820255